News
OGN
13.65
+0.22%
0.03
Organon opens REMS Program for Miudella
TipRanks · 1d ago
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
Barchart · 1d ago
Weekly Report: what happened at OGN last week (0803-0807)?
Weekly Report · 2d ago
Top Organon Executive Cashes In on Major Stock Sale
TipRanks · 6d ago
Weekly Report: what happened at OGN last week (0727-0731)?
Weekly Report · 08/03 09:13
Organon (OGN) Stock Stalls As Margin Compression Keeps Value Debate Alive
Simply Wall St · 08/02 04:27
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Seeking Alpha · 07/31 21:15
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
NASDAQ · 07/31 15:00
Organon Reports Q2 Results Amid Pending Sun Pharma Merger
TipRanks · 07/31 12:50
Organon declares $0.02 dividend
Seeking Alpha · 07/31 12:35
Press Release: Organon Announces Quarterly Dividend
Dow Jones · 07/31 12:30
Organon: Q2 Earnings Snapshot
Barchart · 07/31 07:41
Organon Announces Quarterly Dividend
Barchart · 07/31 07:30
These mid-cap stocks combine A-rated profitability with attractive forward valuations
Seeking Alpha · 07/27 13:59
Weekly Report: what happened at OGN last week (0720-0724)?
Weekly Report · 07/27 09:14
Organon to present results from analysis of Phase 3 trials of VTAMA cream
TipRanks · 07/24 12:11
Organon To Present Results From Post Hoc Analysis Of Pooled Data From Phase 3 Pivotal Trials, ADORING 1 And ADORING 2, Evaluating VTAMA Cream Versus Vehicle At 2026 SPD Annual Meeting
Benzinga · 07/24 12:04
New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
Barchart · 07/24 07:00
Organon Shareholders Approve Merger with Sun Pharma
TipRanks · 07/23 21:28
Organon (OGN) Stock Looks Below Fair Value Despite Weak Earnings Quality
Simply Wall St · 07/23 05:25
More
Webull provides a variety of real-time OGN stock news. You can receive the latest news about ORGANON & CO through multiple platforms. This information may help you make smarter investment decisions.
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.